CSIMarket
 
Edesa Biotech Inc   (EDSA)
Other Ticker:  
 
 
Price: $4.3000 $-0.09 -2.050%
Day's High: $4.6609 Week Perf: -5.49 %
Day's Low: $ 3.88 30 Day Perf: -23.89 %
Volume (M): 5 52 Wk High: $ 8.33
Volume (M$): $ 20 52 Wk Avg: $2.34
Open: $4.03 52 Wk Low: $0.39



 Market Capitalization (Millions $) 13
 Shares Outstanding (Millions) 3
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -8
 Cash Flow (TTM) (Millions $) -4
 Capital Exp. (TTM) (Millions $) 0

Edesa Biotech Inc
Edesa Biotech Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutic treatments for dermatological and gastrointestinal diseases. The company is dedicated to addressing unmet medical needs and improving patient outcomes in these areas.

Edesa Biotech utilizes its proprietary approach to identify and develop small molecules that target specific biological pathways involved in disease pathogenesis. The company's lead product candidate is EB01, a novel non-steroidal, anti-inflammatory cream being developed for the treatment of chronic allergic contact dermatitis.

By leveraging its deep understanding of the underlying disease mechanisms and the potential therapeutic targets, Edesa Biotech aims to develop safe and effective treatments with improved efficacy compared to existing therapies. The company is committed to conducting rigorous clinical trials to evaluate the safety and efficacy profiles of its products.

Edesa Biotech also actively pursues collaborations and partnerships with other pharmaceutical companies and academic institutions to further enhance its drug development capabilities. The company is headquartered in Markham, Ontario, Canada, and primarily operates in North America.


   Company Address: 100 Spy Court Markham 0 ON
   Company Phone Number: 800-9600   Stock Exchange / Ticker: NASDAQ EDSA
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Edesa Biotech Inc

Edesa Biotech Inc Tackles Challenges Head-On: Operating Loss in Q4 2023 Sparks Determination for Triumph

As the July to September 30, 2023 reporting season continues, a number of corporations in the Major Pharmaceutical Preparations sector have unveiled their latest financial results. One such company, Edesa Biotech Inc (EDSA), has recently announced an operating loss of $-2.369663 million for the fourth quarter of the 2023 earnings season. While this may initially seem concerning, it is vital to compare these results to the previous year to gain a better perspective.
When comparing EDSA's operating loss with that of the fourth quarter of 2022, it is evident that the company has made progress. In 2022, the operating loss stood at $-2.836311 million, indicating a positive trend towards reducing losses. This is an encouraging sign for Edesa Biotech Inc as it continues to solidify its business strategy, aiming for long-term economic stability and growth.

Edesa Biotech Inc

Edesa Biotech Inc Makes Significant Strides: Reduces Operating Shortfall by over 64% in Q3 2023

Edesa Biotech Inc: An Emerging Player in the Pharmaceutical Preparations Industry
The Major Pharmaceutical Preparations industry is dominated by big players who have established themselves over the years. However, a number of smaller businesses are now emerging and making their mark in the industry. One such company is Edesa Biotech Inc, which recently revealed its financial performance for the third quarter of 2023.
Edesa Biotech Inc reported an operating shortfall of $-2.064209 million for the third quarter of 2023. While this may seem like a significant loss, it is worth noting that the company has managed to compete more economically compared to the same period in the previous year. In the third quarter of 2022, Edesa Biotech Inc recorded an operating shortfall of $-5.797525 million. This indicates that the company is making progress in improving its financial performance.

Edesa Biotech Inc

Edesa Biotech Inc surprises shareholders with impressive financial turnaround, exceeding expectations in Q1 2023

Edesa Biotech Inc, a healthcare company, surprised its shareholders by posting positive financial results during the earnings cycle for fiscal January to March 31, 2023. The operating shortfall of $-2.410581 million was viewed as a positive surprise, exceeding usual benchmarks. This is a significant improvement from the operating shortfall of $-4.575231 million in the second quarter of 2022, instilling confidence in EDSA among market participants.
Moreover, there was relief on the bottom-line as the diminishing returns have been reduced from the previous year's timeframe. This was a crucial conclusion from the financial time-frame ending second quarter of 2023, with a shortfall of $-2.334 million compared to $-4.569 million in the second quarter of 2022.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com